| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Can placebo controls reduce the number of nonresponders in clinical trials? a power-analytic perspective
|
Leon, Andrew C.
|
|
2001
|
23 |
4 |
p. 596-603
8 p.
|
artikel
|
| 2 |
Comparative efficacy of clarithromycin modified-release and clarithromycin immediate-release formulations in the treatment of lower respiratory tract infection
|
Adam, Dieter
|
|
2001
|
23 |
4 |
p. 585-595
11 p.
|
artikel
|
| 3 |
Consensus statement on the modern therapy of paget's disease of bone from a western osteoporosis alliance symposium
|
Drake, William M.
|
|
2001
|
23 |
4 |
p. 620-626
7 p.
|
artikel
|
| 4 |
Editorial comment
|
Walson, Philip D.
|
|
2001
|
23 |
4 |
p. 519-
1 p.
|
artikel
|
| 5 |
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension
|
Simmons, Steven T
|
|
2001
|
23 |
4 |
p. 604-619
16 p.
|
artikel
|
| 6 |
Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy
|
Hemstreet, Brian
|
|
2001
|
23 |
4 |
p. 520-531
12 p.
|
artikel
|
| 7 |
Mecamylamine: new therapeutic uses and toxicity/risk profile
|
Young, John M.
|
|
2001
|
23 |
4 |
p. 532-565
34 p.
|
artikel
|
| 8 |
Pharmaceutical prices: the debate continues
|
Coons, Stephen Joel
|
|
2001
|
23 |
4 |
p. 628-
1 p.
|
artikel
|
| 9 |
Pharmacokinetics and tolerability of extended-release clarithromycin
|
R.P. Guay, David
|
|
2001
|
23 |
4 |
p. 566-577
12 p.
|
artikel
|
| 10 |
The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate
|
Kaye, Clive M.
|
|
2001
|
23 |
4 |
p. 578-584
7 p.
|
artikel
|
| 11 |
The potential unintended economic consequences of the medicine equity and drug safety act of 2000
|
Vogel, Ronald J.
|
|
2001
|
23 |
4 |
p. 629-643
15 p.
|
artikel
|
Tijdschrift beschrijving